---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-035701"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-10-28T23:59:59+00:00"
generated_at: "2026-06-22T23:07:02.291514+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma Q3 net loss narrows to $2.3M; strategic review with workforce reduction

## Summary
- Net loss of $2.3M ($0.16/sh) narrowed from $4.7M ($0.33/sh) in Q3 2021.
- Cash $43.9M as of Sep 30, 2022; sufficient to fund operations through end of 2023.
- Workforce reduction with ~$0.8M restructuring charges recorded in Q3 2022.
- Strategic review with Ladenburg Thalmann; evaluating acquisition, merger, or other options.
- R&D expenses fell to $1.0M from $3.4M due to completion of rNAPc2 Phase 2b trial enrollment.

## SEC filing metadata
- accession: 0001564590-22-035701
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/abio-8k_20221028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-035701
- JSON: https://secwatch.observer/filing/0001564590-22-035701.json
- Plain text: https://secwatch.observer/filing/0001564590-22-035701.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2022 was $2.3 million, or $0.16 per basic and diluted share, compared to $4.7 million, or $0.33 per basic and diluted share in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm
- Earnings Releases
  Oruka Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On October 28, 2022, ARCA biopharma, Inc., or ARCA, issued a press release reporting financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.